INmune Bio (NASDAQ:INMB) issued its earnings results on Monday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.16, Bloomberg Earnings reports.
INmune Bio stock traded down $0.33 during trading on Tuesday, hitting $5.78. 10,871 shares of the company were exchanged, compared to its average volume of 30,470. The firm has a 50 day simple moving average of $9.12. INmune Bio has a 52 week low of $5.66 and a 52 week high of $11.50.
Separately, Maxim Group set a $13.00 target price on INmune Bio and gave the stock a “buy” rating in a research report on Monday, June 10th.
INmune Bio Company Profile
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Read More: Insider Trading – What You Need to Know
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.